ATTENTION SHAREHOLDERS: Special Situation Alert - Small Cap Street
26 Octubre 2015 - 6:25AM
InvestorsHub NewsWire
NEW YORK, NY – October 26, 2015 -- InvestorsHub NewsWire
-- Small Cap Street makes the connection between sophisticated
investors and high quality micro and small cap companies that are
currently undervalued. We are an issuer of reports written by
experienced financial analysts and who provide a straight forward
assessment of profiled companies. They include stocks traded in the
NYSE, NASDAQ, and OTCBB exchanges.
*Special Situation Alert Coming Tuesday, October 27th,
2015*
Small Cap Street and several other large media providers will be
profiling an exceptional growth company that has some similarities
to our last 200% winner.
This company recently executed a large reverse merger and is flying
way under the radar. With an extremely tiny float we are expecting
this to be one of our best alerts ever.
Be ready at 9:45 am EST on Tuesday, October 27th, 2015
by joining our group here: smallcapstreet.com
To receive profiles in real time, text "Street" to 25827
4 Brief Company Reports -
Viropro, Inc. (OTCBB:
VPRO) through its subsidiaries, is engaged in the contract
research, development, and manufacture of biotherapeutic proteins
for the treatment of various diseases. The company is also involved
in the transfer of its proprietary technologies for industrial
production of biogeneric therapeutic proteins for the treatment of
various diseases, such as cancer, diabetes, hepatitis, or multiple
sclerosis.
VPRO has signed a non-binding Letter of Intent for the acquisition
of NovaRx, a San pioneer in immuno-oncology, in an all-stock
transaction that is expected to close by year-end. NovaRx has
developed a method of activating the body's immune system to
recognize and destroy cancer cells. In a Phase II trial, the
company demonstrated a significant improvement in survival for
patients with non-small cell lung cancer. A Phase III trial did not
achieve its desired endpoint. The company's management
believes that a properly designed and administered Phase III study
will yield different results.
Kallo, Inc. (OTCQB:
KALO) develops and delivers innovative, technologically
advanced and turnkey healthcare solutions in the developing world
and rural communities including infectious disease management,
education and training programs. The company's mobile technology
suite transforms the delivery of rural medicine, disease
management, clinical globalization, and eHealth solutions.
KALO was recognized last month with the Frost & Sullivan 2015
Award for Emerging Market Innovation. This award recognizes Kallo's
unique holistic approach to healthcare delivery. Kallo's modular
approach caters to the specific healthcare needs of each region
through a combination of polyclinics, mobile clinics, teaching
institutions and telemedicine. This system is designed to serve
such emerging nations as Guinea, Senegal, Nigeria, Peru, Brazil,
Cameroon and Chad.
Urban Barns Foods Inc. (OTCQB:
URBF) is a Canadian food producer growing fresh vegetables year
round. Grown in a completely controlled environment, their
vegetables are grown from non-GMO seeds and free of pesticide,
herbicide, and fungicide. Controlled environment means no contact
with the outside world, eliminating the possibilities of
contamination and infection. The company specializes in leafy
vegetables including lettuce and basil that are
Kosher-certified.
URBF has undergone a restructuring of its executives this year
making changes in the Chairman, CEO, and President and Directors
positions. The company’s fiscal year ends July 31st. Recent
financials indicate a drop in shareholder equity, primarily due to
increased debt, and a better bottom line due to a significant cut
in operating expenses.
Elite Pharmaceuticals, Inc. (OTCQB:
ELTP) is a pharmaceutical company developing a pipeline of
pharmacological abuse-deterrent opioid products and niche generic
products. Elite owns generic and OTC products licensed to TAGI
Pharma, Epic Pharma and Valeant Pharmaceuticals International with
seven commercial products currently being sold.
The company has achieved positive top-line results from the Phase 3
pivotal trial of its lead opioid abuse-deterrent candidate,
ELI-200, for the treatment of moderate to severe pain. There were
no serious adverse events or deaths related to ELI-200 reported
during the conduct of the trial. Elite intends to submit a New Drug
Application to the U.S. Food and Drug Administration for
abuse-deterrent ELI-200 by year-end.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and may
make mistakes. This report was prepared for informational purposes
only. A full disclaimer can be found by viewing the full
analyst report. We do not engage in high frequency trading or hold
any positions of profiled company.
For more information and services provided beyond this release
please use contact information provided below. If you notice any
errors or omissions, please notify us below.
Source: Small Cap Street
Contact: editor@smallcapstreet.com
Kallo (CE) (USOTC:KALO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Kallo (CE) (USOTC:KALO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024